Definitive Contract 75D30121C11909

Award Date 9/30/21
Potential Completion Date 9/30/22
Potential Value $1.2M
Federal Agency
CDC Pittsburgh
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Oakland, CA 94612, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Centers for Disease Control and Prevention (CDC) to Kaiser Foundation Hospitals, a division of the non-profit Kaiser Permanente healthcare system, to establish a virtual network to investigate the effectiveness of COVID-19 and influenza vaccines. The contract is a definitive, firm fixed-price award with a ceiling value of $2,587,498.00 and a completion date of September 6, 2027. This contract is not set aside and leverages Kaiser Permanente's...
The Centers for Disease Control and Prevention (CDC) awarded Kaiser Foundation Hospitals, doing business as Kaiser Permanente, a $817,295.00 contract for "INNOVATIVE METHODS TO IMPROVE ESTIMATES OF INFLUENZA VACCINE EFFECTIVENESS FOR DIFFERENT INFLUENZA VACCINE TYPES". The contract is a definitive contract with a cost no fee pricing type, and the period of performance runs through December 30, 2021. There was no set-aside used for this award. The contract was awarded under the CDC's...
This federal contract award to Kaiser Foundation Hospitals, Kaiser Foundation Research Institute Division, doing business as Kaiser Permanente, is valued at $1,772,230.00. It was awarded by the Centers for Disease Control and Prevention (CDC) on April 9, 2020 and has an ultimate completion date of August 6, 2023. The contract is for "INNOVATIVE METHODS TO INFORM ESTIMATES OF VACCINE EFFECTIVENESS USING INFORMATION" and is a firm fixed-price definitive contract. No set-aside was used....
This is a definitive federal contract awarded by the Centers for Disease Control and Prevention (CDC) to Kaiser Foundation Hospitals, doing business as Kaiser Permanente, for a prospective observational cohort study to assess the effectiveness of SARS-CoV-2 vaccines. The $55,223,588.00 contract has an ultimate completion date of December 31, 2024 and is a cost-no-fee arrangement. The contract does not have a set-aside designation. Kaiser Permanente is collaborating with the University of...
The Centers for Disease Control and Prevention (CDC) awarded a $11,470,897.31 firm fixed price contract to Kaiser Foundation Hospitals, doing business as Kaiser Permanente, a non-profit healthcare provider and research organization. The contract, titled "CDC CFA EPID STUDIES", is not set aside for any special business designation. The contract supports epidemiology studies and investigations, leveraging Kaiser Permanente's access to large-scale electronic medical record data covering...
The U.S. Centers for Disease Control and Prevention (CDC) awarded a $748,171 delivery order contract to Kaiser Foundation Hospitals, doing business as Kaiser Permanente, for PEDIATRIC COVID VACCINATION services. This contract is part of the CDC's Clinical Immunization Safety Assessment (CISA) program, a $86 million indefinite delivery vehicle that supports epidemiological and clinical research to evaluate vaccine safety. The contract has no set-aside designation, reflecting Kaiser Permanente's...
This delivery order contract was awarded by the Centers for Disease Control and Prevention (CDC) to Kaiser Foundation Hospitals, a non-profit healthcare provider and research organization doing business as Kaiser Permanente. The contract is part of the CDC's Clinical Immunization Safety Assessment (CISA) program and has a ceiling value of $682,236. The order supports COVID-19 pediatric research at Kaiser Permanente, which has a long history of conducting evidence-based clinical research and...
This firm fixed-price contract was awarded by the Centers for Disease Control and Prevention (CDC) to Kaiser Foundation Hospitals, a non-profit healthcare provider and research organization operating as Kaiser Permanente. The contract, valued at $5,713,197.00, is for a "Virtual Network to Investigate the Clinical Epidemiology of Influenza and the Effectiveness of Influenza Vaccines." The purpose is to collect high-quality electronic health record (EHR) data to improve influenza...
This federal contract was awarded by the Department of Health and Human Services Centers for Disease Control and Prevention to Kaiser Foundation Hospitals, a division of the Kaiser Foundation Research Institute doing business as Kaiser Permanente. The $387,865.87 firm fixed price delivery order contract is for the Vaccine Safety Datalink Project, which supports critical functions for vaccine safety. The contract has no set-aside designation and was completed on September 19, 2019. Kaiser...
This is a purchase order award by the Centers for Disease Control and Prevention (CDC) to Kaiser Foundation Hospitals, a non-profit healthcare provider and research organization doing business as Kaiser Permanente. The $116,746 firm fixed-price contract, awarded on September 30, 2015, is for unspecified products or services with a completion date of December 31, 2016. The award is not set aside for any particular type of business. Kaiser Permanente is an established federal contractor that...

This $1.2 million firm fixed price contract from the Centers for Disease Control and Prevention (CDC) will fund Kaiser Foundation Hospitals to evaluate influenza and SARS-CoV-2 vaccine effectiveness against outpatient, laboratory-confirmed illness. Kaiser Permanente will serve as the prime contractor, with Marshfield Clinic, Inc. providing laboratory testing services as a subcontractor. The contract furthers CDC's mission to monitor and improve vaccine effectiveness through epidemiologic and clinical research. It is anticipated that Kaiser Permanente will analyze approximately 2,000 specimens for influenza and COVID-19 sent to Marshfield Clinic's laboratory using real time reverse transcription polymerase chain reaction testing. Marshfield Clinic will extract viral RNA from the samples and conduct multiplex testing on CDC-validated platforms. Results will be reported to enrolling clinical sites through an existing research electronic data capture database. The contract advances CDC's goal of assessing influenza and SARS-CoV-2 vaccine impact on mild and moderate outpatient illness.

Generated 3/1/24, 10:00 AM